News | February 17, 2026
EU to withdraw Levamisole medicines over risk of rare, deadly brain disorder
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Subscribe To Our Newsletter & Stay Updated
